Cardiac Dose Control and Optimization Strategy for Left Breast Cancer Radiotherapy With Non-Uniform VMAT Technology

Purpose: A novel in-house technology “Non-Uniform VMAT (NU-VMAT)” was developed for automated cardiac dose reduction and treatment planning optimization in the left breast radiotherapy. Methods: The NU-VMAT model based on I GM (gantry MLC Movement coefficient index) was established to optimize the v...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jianjian Qiu PhD, Shujun Zhang MS, Bo Lv MS, Xiangpeng Zheng MD
Formato:	article
Lenguaje:	EN
Publicado:	SAGE Publishing 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/8f7a4116758943cdb817204c1a29ef64
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8f7a4116758943cdb817204c1a29ef64
record_format	dspace
spelling	oai:doaj.org-article:8f7a4116758943cdb817204c1a29ef642021-11-21T02:04:36ZCardiac Dose Control and Optimization Strategy for Left Breast Cancer Radiotherapy With Non-Uniform VMAT Technology1533-033810.1177/15330338211053752https://doaj.org/article/8f7a4116758943cdb817204c1a29ef642021-11-01T00:00:00Zhttps://doi.org/10.1177/15330338211053752https://doaj.org/toc/1533-0338Purpose: A novel in-house technology “Non-Uniform VMAT (NU-VMAT)” was developed for automated cardiac dose reduction and treatment planning optimization in the left breast radiotherapy. Methods: The NU-VMAT model based on I GM (gantry MLC Movement coefficient index) was established to optimize the volumetric modulated arc therapy (VMAT) MLC movement and modulation intensity in certain gantry angles. The ESAPI embedded in Eclipse® was employed to connect TPS and the optimization program via I/O relevant DICOM RT files. The adjuvant whole-breast radiotherapy of 14 patients with left breast cancer was replanned using our NU-VMAT technology in comparison with VMAT and IMRT technology. Dosimetric parameters including D 1% , D 99% , and D mean of PTV, V 5 , V 10 , and V 20 of ipisilateral lung, V 5 , D 20 , D 30 , and D mean of heart, monitor units (MUs), and delivery time derived from IMRT, VMAT, and NU-VMAT plans were evaluated for plan quality and delivery efficiency. The quality assurance (QA) was conducted using both point-dose and planar-dose measurements for all treatment plans. Results: The I GM−NU−VMAT curves with plan optimization (range from 50% to 147%) were converged more significantly than I GM - VMAT curves (range from 0% to 297%). The dose distribution requirements of the target and normal tissues could be met using IMRT, VMAT, or NU-VMAT; the lowest D mean was achieved in NU-VMAT plans (5.38 ± 0.46 Gy vs 5.63 ± 0.61 Gy in IMRT and 7.95 ± 0.52 Gy in VMAT plans). Statistically significant differences were found in terms of delivery time and MU when comparing IMRT with VMAT and NU-VMAT plans ( P < .05). In comparison with IMRT plans, the MU and delivery time in NU-VMAT plans dramatically decreased by 69.8% and 28.4%, respectively. Moreover, NU-VMAT plans showed a high gamma passing rate (96.5% ± 1.11) in plane dose verification and minimal dose difference (2.4% ± 0.19) in point absolute dose verification. Conclusion: Our non-uniform VMAT facilitated the treatment strategy optimization for left breast cancer radiotherapy with dosimetric advantage in cardiac dose reduction and delivery efficiency in comparison with the conventional VMAT and IMRT.Jianjian Qiu PhDShujun Zhang MSBo Lv MSXiangpeng Zheng MDSAGE PublishingarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENTechnology in Cancer Research & Treatment, Vol 20 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Jianjian Qiu PhD Shujun Zhang MS Bo Lv MS Xiangpeng Zheng MD Cardiac Dose Control and Optimization Strategy for Left Breast Cancer Radiotherapy With Non-Uniform VMAT Technology
description	Purpose: A novel in-house technology “Non-Uniform VMAT (NU-VMAT)” was developed for automated cardiac dose reduction and treatment planning optimization in the left breast radiotherapy. Methods: The NU-VMAT model based on I GM (gantry MLC Movement coefficient index) was established to optimize the volumetric modulated arc therapy (VMAT) MLC movement and modulation intensity in certain gantry angles. The ESAPI embedded in Eclipse® was employed to connect TPS and the optimization program via I/O relevant DICOM RT files. The adjuvant whole-breast radiotherapy of 14 patients with left breast cancer was replanned using our NU-VMAT technology in comparison with VMAT and IMRT technology. Dosimetric parameters including D 1% , D 99% , and D mean of PTV, V 5 , V 10 , and V 20 of ipisilateral lung, V 5 , D 20 , D 30 , and D mean of heart, monitor units (MUs), and delivery time derived from IMRT, VMAT, and NU-VMAT plans were evaluated for plan quality and delivery efficiency. The quality assurance (QA) was conducted using both point-dose and planar-dose measurements for all treatment plans. Results: The I GM−NU−VMAT curves with plan optimization (range from 50% to 147%) were converged more significantly than I GM - VMAT curves (range from 0% to 297%). The dose distribution requirements of the target and normal tissues could be met using IMRT, VMAT, or NU-VMAT; the lowest D mean was achieved in NU-VMAT plans (5.38 ± 0.46 Gy vs 5.63 ± 0.61 Gy in IMRT and 7.95 ± 0.52 Gy in VMAT plans). Statistically significant differences were found in terms of delivery time and MU when comparing IMRT with VMAT and NU-VMAT plans ( P < .05). In comparison with IMRT plans, the MU and delivery time in NU-VMAT plans dramatically decreased by 69.8% and 28.4%, respectively. Moreover, NU-VMAT plans showed a high gamma passing rate (96.5% ± 1.11) in plane dose verification and minimal dose difference (2.4% ± 0.19) in point absolute dose verification. Conclusion: Our non-uniform VMAT facilitated the treatment strategy optimization for left breast cancer radiotherapy with dosimetric advantage in cardiac dose reduction and delivery efficiency in comparison with the conventional VMAT and IMRT.
format	article
author	Jianjian Qiu PhD Shujun Zhang MS Bo Lv MS Xiangpeng Zheng MD
author_facet	Jianjian Qiu PhD Shujun Zhang MS Bo Lv MS Xiangpeng Zheng MD
author_sort	Jianjian Qiu PhD
title	Cardiac Dose Control and Optimization Strategy for Left Breast Cancer Radiotherapy With Non-Uniform VMAT Technology
title_short	Cardiac Dose Control and Optimization Strategy for Left Breast Cancer Radiotherapy With Non-Uniform VMAT Technology
title_full	Cardiac Dose Control and Optimization Strategy for Left Breast Cancer Radiotherapy With Non-Uniform VMAT Technology
title_fullStr	Cardiac Dose Control and Optimization Strategy for Left Breast Cancer Radiotherapy With Non-Uniform VMAT Technology
title_full_unstemmed	Cardiac Dose Control and Optimization Strategy for Left Breast Cancer Radiotherapy With Non-Uniform VMAT Technology
title_sort	cardiac dose control and optimization strategy for left breast cancer radiotherapy with non-uniform vmat technology
publisher	SAGE Publishing
publishDate	2021
url	https://doaj.org/article/8f7a4116758943cdb817204c1a29ef64
work_keys_str_mv	AT jianjianqiuphd cardiacdosecontrolandoptimizationstrategyforleftbreastcancerradiotherapywithnonuniformvmattechnology AT shujunzhangms cardiacdosecontrolandoptimizationstrategyforleftbreastcancerradiotherapywithnonuniformvmattechnology AT bolvms cardiacdosecontrolandoptimizationstrategyforleftbreastcancerradiotherapywithnonuniformvmattechnology AT xiangpengzhengmd cardiacdosecontrolandoptimizationstrategyforleftbreastcancerradiotherapywithnonuniformvmattechnology
_version_	1718419377358897152

Cardiac Dose Control and Optimization Strategy for Left Breast Cancer Radiotherapy With Non-Uniform VMAT Technology

Ejemplares similares